Skip to main content

NeoGenomics, Inc.

corporate_fare Company Profile

NeoGenomics, Inc.

NEO·NASDAQ·Industrial Applications And Services·CIK 0001077183

NeoGenomics, Inc. provides oncology diagnostic testing and consultative services. These services include technical laboratory services and professional interpretation of test results by licensed physicians or molecular experts specializing in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. As of December 31, 2025, NeoGenomics operated College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments of 1988 (CLIA) certified laboratories in Fort Myers, Florida; Aliso Viejo and Carlsbad, California; Durham, North Carolina; Ramsey, New Jersey; and Houston, Texas. It also operated an International Organization for Standardization (ISO) certified, CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. Additionally, the company has several small, non-processing laboratory locations across the United States for analysis services. NeoGenomics offers Cytogenetics (karyotype analysis), which is the study of normal and abnormal chromosomes and their relationship to disease, involving the analysis of chromosome structure to identify changes from normal patterns. These studies provide diagnostic, prognostic, and occasionally predictive information for patients with hematological malignancies. The company also offers Fluorescence In-Situ Hybridization (FISH), a molecular cytogenetic technique that detects and localizes specific DNA sequences and genes on chromosomes using fluorescent probes visualized by fluorescence microscopy.

NeoGenomics, Inc. (NASDAQ:NEO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 23 items for NEO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • NeoGenomics Reports Full-Year 2025 Results with Increased Loss, Significant Impairments, and Key Patent Litigation Win
  • NeoGenomics Reports Strong 2025 Revenue Growth, Positive 2026 Guidance, and Strategic Product Launch
  • NeoGenomics Reports Strong Preliminary Q4 & FY25 Revenue, Announces CFO Transition

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$727.33M
Net Income
-$108.03M
Op. Cash Flow
$5.23M
Free Cash Flow
-$21.78M
Gross Profit
$314.29M
Operating Income
-$115.88M
Cash & Equivalents
$159.62M
Total Debt
$341.86M
Debt / Equity
0.41×
Net Margin
-14.9%
Shares Outstanding
128.15M sh
Source: 10-K · filed 2026-02-17 · accession 0001077183-26-000010
$14.79 -0.20% today
52-week range · as of 2026-10-28 $7.07 – $20.15
Market cap
$1.92B
Volume
1.2M (0.7× avg)
3-mo avg 1.7M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NEO - Filings & News (Page 2)

NEO
Feb 17, 2026, 4:17 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $11.35
Real-time Price: $14.79 info
Change: +$3.44 (+30%) info
Market Cap: $1.918B info
NEO
Feb 17, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.20
Real-time Price: $14.79 info
Change: +$3.59 (+32%) info
Market Cap: $1.918B info
NEO
Jan 12, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.25
Real-time Price: $14.79 info
Change: +$1.54 (+12%) info
Market Cap: $1.918B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets